论文部分内容阅读
目的制备抗SARS-CoV免疫球蛋白(ASI)乳酸-羟乙酸共聚物(PLGA)微球,研究其体外释放性质及中和SARS活性。方法采用复乳溶剂挥发法制备ASI微球,以激光粒度测定仪测定微球的平均粒径,以BCA法及微量BCA法测定微球的蛋白含量及蛋白从微球的释放。用ELISA法考察从微球中释放出的ASI的活性。结果ASI微球粒径均匀,平均粒径为15.87 μm,蛋白包裹率为70.1%,载药量为6.3%,微球中包裹的ASI与原蛋白溶液相比活性不损失。结论采用复乳溶剂挥发法,通过控制一定的因素,可以得到具有较高包封率的ASI微球。
OBJECTIVE To prepare anti-SARS-CoV immunoglobulin (ASI) lactic acid-glycolic acid copolymer (PLGA) microspheres and study their in vitro release properties and neutralization of SARS activity. Methods The ASI microspheres were prepared by double emulsion method. The average particle size of microspheres was determined by laser particle sizer. The protein content and protein release from microspheres were determined by BCA method and micro BCA method. The activity of ASI released from the microspheres was examined by ELISA. Results ASI microspheres had a uniform particle size of 15.87 μm, a protein encapsulation rate of 70.1% and a drug loading of 6.3%. The activity of ASI encapsulated in microspheres was no different from that of the original protein solution. Conclusions ASI microspheres with higher entrapment efficiency can be obtained by controlling the amount of encapsulation by the complex emulsion solvent evaporation method.